Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 15, 2017
Pharmacy Choice - Pharmaceutical News - Allergan Receives Approval for Ozurdex Dexamethasone Intravitreal Implant 0.7 mg in China for the Treatment of Retinal Vein Occlusion RVO - December 15, 2017

Pharmacy News Article

 11/17/17 - Allergan Receives Approval for Ozurdex Dexamethasone Intravitreal Implant 0.7 mg in China for the Treatment of Retinal Vein Occlusion RVO

By a News Reporter-Staff News Editor at Health & Medicine Week Allergan plc (NYSE: AGN) announced that it has received an Imported Drugs License (IDL) from the Chinese Food and Drug Administration (CFDA) to market Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment of adult patients with macular edema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) (see also Pharmaceutical Companies).

Ozurdex is the first approved intravitreal injection for RVO in China. Retinal vein occlusion (RVO) is the second most common type of retinal vascular disorder after diabetic retinal disease and one of the most common causes of sudden, painless, unilateral loss of vision.i It is estimated that there are around 7.4 million patients in China with RVO who require treatment. ii,iii,iv

"Ozurdex addresses a clear unmet need in Chinese patients with RVO, a potentially blinding disease if left untreated," explained David Nicholson, Chief Research and Development Officer at Allergan. "Inflammation is a critical component in RVO leading to macular edema and potential vision loss. Ozurdex suppresses mediators of inflammation and delivers rapid and sustained visual gains.v,vi As the prevalence of eye diseases and blindness grows in Asiavii, we are committed to improving access to innovative medicines and individualised treatments like Ozurdex that provide rapid improvements in visual acuityv and importantly, reduce the burden of injection for patients."

Ozurdex is a biodegradable implant containing dexamethasone, an anti-inflammatory corticosteroid, in a single use applicator. Following an intravitreal injection into the back of the eye, the implant slowly releases the dexamethasone directly to the retina over a period of several months.viii

"As a result of its clinical performance, Ozurdex was put on the priority approval list by the Chinese Food and Drug Administration (CFDA). The approval of Ozurdex underscores our commitment to bring more innovative eye care solutions to tackle unmet medical needs in China. Coming next, Allergan China will be accelerating access to Ozurdex for Chinese hospitals - and more importantly to Chinese patients," said Shirley Zhao, Allergan China President.

The clinical efficacy and safety of Ozurdex has been assessed in three phase III randomised, double-masked, sham-controlled studies. Based on the pooled analysis of the two global pivotal studies RVO1 and RVO2 as well as the China registration study RVO3 results, treatment with Ozurdex showed statistically significant improvements in visual gains compared with sham treatment. The most commonly-reported adverse events following treatment with Ozurdex are those frequently observed with ophthalmic steroid treatment or intravitreal injections (elevated IOP, cataract formation and conjunctival or vitreal haemorrhage respectively).vi

Commenting on the announcement, Marc Princen, Allergan International President said, "We are delighted to receive this approval, which means we can now provide RVO patients in China with an effective treatment option. China is a very important market for Allergan; it's the second largest pharmaceutical market in the world after the US and furthermore has the largest number of people with visual impairment and blindness globally. We are committed to bringing innovative treatments to these patients and help improve their quality of life."

Keywords for this news article include: Asia, Pharmaceutical Companies, China, Hormones, Allergan plc, Inflammation, Glucocorticoids, Venous Thrombosis, Drugs and Therapies, Ophthalmic Steroids, Dexamethasone Therapy, Retinal Vein Occlusion, Embolism and Thrombosis, Ophthalmic Preparations, Adrenal Cortical Steroids, Eye Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Dec 15: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Dec 17: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Dec 18: Management of Alcohol Use Disorders
Dec 19: Medication Adherence: To Take or Not to Take…That is the Problem
Dec 20: Type II Diabetes: Case Studies and Management Options
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415